Ponatinib was approved, in 2012, by the FDA for the treatment of resistant or intolerant CML and Ph+ ALL, as a third generation multikinase inhibitor targeting BCR-ABL, SRC, EGFR, PDGFR, FGFR, and VEGFR [142]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.